|
Press Releases |
|
|
|
Thursday, August 22, 2024 |
|
Leqembi (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain |
Eisai Co., Ltd. and Biogen Inc.announced today that the humanized amyloid-beta(Abeta) monoclonal antibody "Leqembi" (brand name, generic name: lecanemab) has been granted a Marketing Authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain. more info >> |
|
Wednesday, August 14, 2024 |
|
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in the United Arab Emirates |
Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved humanized anti-soluble aggregated amyloid-beta (Abeta;) monoclonal antibody "LEQEMBI" (lecanemab) for the treatment of Alzheimer's disease (AD). more info >> |
|
Tuesday, August 6, 2024 |
|
Eisai: Update Regarding the Regulatory Status of LEQEMBI Subcutaneous Formulation |
Eisai Co., Ltd. reconfirmed that the regulatory status for anti-amyloid beta (Aβ) protofibril antibody LEQEMBI (generic name:lecanemab) subcutaneous (SC) autoinjector, explained at the Financial Disclosure Meeting on August 2, 2024, is as follows. more info >> |
|
Wednesday, July 31, 2024 |
|
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at AAIC 2024 |
Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings for lecanemab-irmb (U.S. brand name: LEQEMBI), an anti-amyloid beta (Abeta) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Alzheimer's Association International Conference (AAIC) 2024, held in Philadelphia, and virtually. more info >> |
|
Monday, July 29, 2024 |
|
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union |
Eisai Co., Ltd. and Biogen Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the Marketing Authorization Approval (MAA) for the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody lecanemab as treatment for early AD (mild cognitive impairment due to Alzheimer?s disease (AD) and mild AD). more info >> |
|
Thursday, July 25, 2024 |
|
Eisai and EcoNaviSta Enter into Business Alliance Agreement Aimed at Building a Dementia Ecosystem and Commence Collaboration |
Eisai Co., Ltd. and EcoNaviSta Inc. announced today that they have entered into a business alliance agreement and commenced collaboration with the aim of building an ecosystem in the area of dementia, which is a pressing matter in Japan's super-aging society. more info >> |
|
Tuesday, July 23, 2024 |
|
Eisai to Present Dual-Acting Lecanemab Three-Year Efficacy and Safety Data and Discuss Long-Term Outcomes of Continued Treatment at the Alzheimer's Association International Conference 2024 |
The conference will be held in Philadelphia and virtually from July 28 to August 1, 2024. Eisai will present data and research in four (4) oral and 15 poster presentations at the meeting and will host two (2) sessions on lecanemab. more info >> |
|
Tuesday, July 16, 2024 |
|
エーザイ、ホスラブコナゾールのアジア・オセアニアにおけるライセンス契約を佐藤製薬と締結 |
エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫)は、このたび、抗真菌剤ホスラブコナゾールについて、真菌性疾患に対するアジア・オセアニアにおける開発および商業化に関するライセンス契約を佐藤製薬株式会社(本社:東京都、以下 佐藤製薬)と締結したことをお知らせします。 more info >> |
|
Friday, July 12, 2024 |
|
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel |
Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (generic name: lecanemab) has been approved in Israel as a treatment of Alzheimer's disease (AD). more info >> |
|
エーザイとバイオジェン、「レケンビ」(レカネマブ)がイスラエルにおいてアルツハイマー病治療剤として承認を取得 |
エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫、以下 エーザイ)と バイオジェン・インク(Nasdaq:BIIB、本社:米国マサチューセッツ州ケンブリッジ、 CEO:Christopher A. Viehbacher、以下 バイオジェン)は、このたび、ヒト化抗ヒト可溶性アミロイドβ(Aβ)凝集体モノクローナル抗体「レケンビ®」(一般名:レカネマブ)について、イスラエルにおいて新薬承認を取得したことをお知らせします。 more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Baguio Wins Two Contracts for Smart Food Waste Recycling Machines and Smart Balances from EPD
Jan 20, 2025 21:20 HKT/SGT
|
|
|
碧瑶赢得环保署智能厨余回收机及智能磅两份合约
Jan 20, 2025 21:12 HKT/SGT
|
|
|
碧瑤贏得環保署智能廚餘回收機及智能磅兩份合約
Jan 20, 2025 20:41 HKT/SGT
|
|
|
DENSO Exhibits at Bharat Mobility Global Expo 2025, New Delhi
Jan 20, 2025 20:26 JST
|
|
|
Transforming Philippine Healthcare: The 2025 Philippine Hospital & Healthcare Digitalization Summit
Jan 20, 2025 16:59 HKT/SGT
|
|
|
Q2 Metals Announces Details of its Expansion Drill Program for the Cisco Lithium Project in Eeyou Istchee James Bay, Quebec
Jan 20, 2025 16:05 HKT/SGT
|
|
|
Celebrate Chinese New Year with Vibrant Festivities at Spritzer EcoPark
Jan 20, 2025 15:30 HKT/SGT
|
|
|
三菱重工、人事異動を発表
Jan 20, 2025 15:30: JST
|
|
|
Hitachi Acquires a Sales and Maintenance Service Company for Large Motors in the United States
Jan 20, 2025 15:07 JST
|
|
|
三菱造船とTPFC、タブレット端末を利用したポータブル運航支援システム「ナビン」のリース販売を開始
Jan 20, 2025 14:00: JST
|
|
|
Suzuki's First BEV "e VITARA" Adopts eAxle
Jan 20, 2025 13:58 JST
|
|
|
Honda、「FREED e:HEV」を一部改良
Jan 20, 2025 11:20: JST
|
|
|
Green Rain Solar Inc.(現代公司 The Now Corporation (OTC:NWPN) 的子公司)宣布推出帶有整合灌溉和備用電力系統的自給式太陽能溫室
Jan 20, 2025 11:00 HKT/SGT
|
|
|
Hypertec Cloud 與 Potentia 合作推動可持續 AI 雲端擴展,在北美新增 480MW 的平衡容量
Jan 20, 2025 11:00 HKT/SGT
|
|
|
Honda Presents the World Premier of BF300 Large-size Outboard Motor at the Dusseldorf Boat Show 2025
Jan 20, 2025 11:36 JST
|
|
|
|
More News >> |
|
|
|
|
|